2. Lee H, Kim J, Park G, Choi H. Characteristics and trends of tuberculosis deaths in the Republic of Korea, 2021. Public Health Weekly Report 2023;16:563–577.

3. Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One 2015;10:e0119332.

4. Nicholson TJ, Hoddinott G, Seddon JA, et al. A systematic review of risk factors for mortality among tuberculosis patients in South Africa. Syst Rev 2023;12:23.

5. Sun Y, Harley D, Vally H, Sleigh A. Comparison of characteristics and mortality in multidrug resistant (MDR) and non-MDR tuberculosis patients in China. BMC Public Health 2015;15:1027.

6. Alemu A, Bitew ZW, Worku T, Gamtesa DF, Alebel A. Predictors of mortality in patients with drug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2021;16:e0253848.

7. Edessa D, Adem F, Hagos B, Sisay M. Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: a meta-analysis of 43 cohort studies. PLoS One 2021;16:e0261149.

8. Min J, Kim JS, Kim HW, et al. Clinical profiles of early and tuberculosis-related mortality in South Korea between 2015 and 2017: a cross-sectional study. BMC Infect Dis 2019;19:735.

9. Kwon YS, Kim YH, Song JU, et al. Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study. J Korean Med Sci 2014;29:1226–1231.

10. Lee J, Nam HW, Choi SH, et al. Comparison of early and late tuberculosis deaths in Korea. J Korean Med Sci 2017;32:700–703.

11. Chung S, Seon JY, Lee SH, et al. The relationship between socio-demographic factors and tuberculosis mortality in the Republic of Korea during 2008–2017. Front Public Health 2021;9:691006.

12. Jeong D, Kang HY, Kim J, et al. Cohort profile: Korean Tuberculosis and Post-Tuberculosis Cohort constructed by linking the Korean National Tuberculosis Surveillance System and National Health Information Database. J Prev Med Public Health 2022;55:253–262.

13. Choi H, Mok J, Kang YA, et al. Nationwide treatment outcomes of patients with multidrug/rifampin-resistant tuberculosis in Korea, 2011–2017: a retrospective cohort study (Korean TB-POST). J Korean Med Sci 2023;38:e33.

14. Choi H, Mok J, Kang YA, et al. Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis. ERJ Open Res 2023;9:00135–2023.

15. World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020 [Internet] Geneva: World Health Organization, c2013. [cited 2024 Jan 20]. Available from: https://www.who.int/publications/i/item/9789241505345. 16. Hwang H, Kang H, Kwon YS, Jeon D, Shim TS, Yim JJ. Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid. Clin Infect Dis 2021;73:1362–1369.

17. Mok J, Lee M, Kim DK, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet 2022;400:1522–1530.

18. Nyang’wa BT, Berry C, Kazounis E, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med 2022;387:2331–2343.

19. Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis 2011;15:871–885.

20. Hagiya H, Koyama T, Zamami Y, et al. Trends in incidence and mortality of tuberculosis in Japan: a population-based study, 1997–2016. Epidemiol Infect 2018;147:e38.

21. Pedrazzoli D, Kranzer K, Thomas HL, Lalor MK. Trends and risk factors for death and excess all-cause mortality among notified tuberculosis patients in the UK: an analysis of surveillance data. ERJ Open Res 2019;5:00125–2019.

22. Negin J, Abimbola S, Marais BJ. Tuberculosis among older adults--time to take notice. Int J Infect Dis 2015;32:135–137.

23. Byng-Maddick R, Noursadeghi M. Does tuberculosis threaten our ageing populations? BMC Infect Dis 2016;16:119.

24. Barrett J. Why are people still dying from TB in low-burden countries? Int J Tuberc Lung Dis 2022;26:91–92.

25. Min J, Kim HW, Kim JS. Tuberculosis: Republic of Korea, 2021. Tuberc Respir Dis (Seoul) 2023;86:67–69.

26. Teo AKJ, Rahevar K, Morishita F, et al. Tuberculosis in older adults: case studies from four countries with rapidly ageing populations in the western pacific region. BMC Public Health 2023;23:370.

27. Teo AKJ, Morishita F, Islam T, et al. Tuberculosis in older adults: challenges and best practices in the Western Pacific Region. Lancet Reg Health West Pac 2023;36:100770.

28. Duarte R, Lönnroth K, Carvalho C, et al. Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology 2018;24:115–119.

29. Samuels JP, Sood A, Campbell JR, Ahmad Khan F, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep 2018;8:4980.

30. Mutembo S, Mutanga JN, Musokotwane K, et al. Urban-rural disparities in treatment outcomes among recurrent TB cases in Southern Province, Zambia. BMC Infect Dis 2019;19:1087.

31. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017; Ahmad N, Ahuja SD, et al.; Akkerman OW. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018;392:821–834.

32. Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018;6:699–706.